Category - Markets

Canaccord Genuity initiated coverage of Natera (NASDAQ:NTRA) with a “buy” rating and $18 price target. The stock is changing hands at $11.66 in afternoon trading on Jan. 6. Natera is the market leader in the $2.5...

H.C. Wainwright initiated coverage of Calithera Biosciences (NASDAQ:CALA) with a “buy” rating and $9 price target. The stock closed at $3.95 on Jan. 5. Calithera is developing oral drugs that target feeding of cancer...

Leerink initiated coverage of Achaogen (NASDAQ:AKAO) with an “outperform” rating and $21 price target. The shares were changing hands at $13.90 in afternoon trading on Jan. 4. Achaogen is developing lead product...

Ladenburg Thalmann upgraded Codexis (NASDAQ:CDXS) to “buy” from “neutral” with a new price target of $6.25. The shares were quoted at $4.65 in afternoon trading on Jan. 4. Analyst Kevin DeGeeter cited growing confidence...

Common shares of 3D Signatures (TSX-V:DXD) have started trading on the OTCQB Venture Market in the U.S. under the symbol, TDSGF, and on the Frankfurt Stock Exchange (FSE) in Germany under the symbol, 3D0. 3D Signatures...

BTIG launched coverage of Intra-Cellular Therapies (NASDAQ:ITCI) with a “buy” rating and $44 price target, saying there is considerable promise for the company’s antipsychotic, ITI-007, in multiple indications. The...

H.C. Wainwright initiated coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and $14 price target. The stock closed at $3.59 on Dec. 21. “The SMART Linker technology is key to our investment...

BTIG initiated coverage of CoLucid Pharmaceuticals (NASDAQ:CLCD) with a “buy” rating and $58 price target, calling the company’s Lasmiditan drug candidate a game changer in acute migraine. The stock closed at $36.16 on...

Ladenburg Thalmann launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $2.70 price target. The stock closed at $1.24 on Dec. 20. Cellectar is focused on development of phospholipid-ether...

Roth Capital Partners initiated coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $20 price target. The stock closed at $13.22 on Dec. 20. Iridex is an ophthalmic medical device company focused on development and...